Copaxone, Rebif, Avonex, Betaseron , Aubagio, Tecfidera and Gilenya are the preferred MS agents. Non-preferred products will be considered if patient has had an inadequate response, intolerable side effects, or a contraindication to 2 ... Retrieve Full Source
SPECIALTY GUIDELINE MANAGEMENT - Provider.carefirst.com
Gilenya SGM P2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. ... Fetch Content
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - Tecfidera
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE TECFIDERA is indicated for the treatment of patients with relapsing forms of multiple sclerosis. ... Document Viewer
Multiple Sclerosis MCY - Mercy Care Plan
Copaxone, Rebif, Avonex, Betaseron , Aubagio, Tecfidera and Gilenya are the preferred MS agents. Non-preferred products will be considered if patient has had an inadequate response, intolerable side effects, or a contraindication to 2 ... Document Viewer
Package Leaflet: Information For The User - Medicines
Package leaflet: Information for the user Gilenya 0.25 mg hard capsules Gilenya 0.5 mg hard capsules fingolimod This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. ... View Full Source
WARNINGS AND PRECAUTIONS - Allergan
VIIBRYD should be down tapered from the 40 mg once daily dose to 20 mg once daily for 4 days, followed by 10 mg once daily for 3 days. Patients taking VIIBRYD 20 mg once daily should be tapered to 10 mg once daily for 7 days. 3 DOSAGE FORMS AND STRENGTHS . VIIBRYD Tablets are available as 10 mg, 20 mg and 40 mg film-coated tablets. ... Fetch Content
MEDICAL POLICY STATEMENT - CareSource
If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination. Gilenya [package insert]. East Hanover, NJ: Novartis ... Doc Viewer
PATIENT INFORMATION A HALAVEN (HAL-ih-ven) HALAVEN (eribulin ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HALAVEN safely and HALAVEN® (eribulin mesylate) injection, for intravenous use See 17 for PATIENT COUNSELING INFORMATION and FDA-approved Patient Labeling ... Fetch Full Source
NDA22-527 GILENYA (fingolimod) 0.5mg Capsules
Monitoring related to these risks, based on relevant sections of the revised Package Insert (PI) dated May 2015. The letter also includes information about the GILENYA GILENYA should be ... Fetch Here
GILENYA (fingolimod) - Caremark
Gilenya (fingolimod) is a sphingosine-1-phosphate-receptor (S1PR) modulator that binds to receptors in the body that block progression of lymphocytes (white blood cells) into the blood and may reduce the movement of lymphocytes into the central nervous system. ... Content Retrieval
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Alzheimer’s Disease EXELON is indicated for the treatment of mild to moderate dementia of the Alzheimer's type (AD). ... Get Doc
Clinical Pharmacy Program Guidelines For Multiple Sclerosis ...
Gilenya® (fingolimod) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. 6 Due to the risk of a decrease in heart rate and/or atrioventricular conduction after first dose of Gilenya, all patients should be observed for signs and ... View Document
SPECIALTY GUIDELINE MANAGEMENT - CareSource
FDA-Approved Indication: Gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals ... Fetch Content
Avonex Prescribing Information English Avonex Prescribing ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVONEX safely and effectively. See full prescribing information for AVONEX. ... Read Document
WARNINGS AND PRECAUTIONS Hepatic Injury: Monitor Liver ...
Treatment initiation Patients should start treatment with 63 micrograms on day 1. On day 15 (14 days later), the dose is increased to 94 micrograms, reaching the full dose of 125 micrograms on day 29 (after another ... Document Viewer
Multiple Sclerosis - Wellmark Blue Cross And Blue Shield
Multiple Sclerosis . BENEFIT APPLICATION . Benefit determinations are based on the applicable contract language in effect at the time the services were • Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2015. ... View This Document
Update: Gilenya First Dose Administration .... Still Don't ...
Dr. Daniel Kantor (Medical Director of Neurologique) has a frank discussion with his patient about the recent (April 2012) change to the package insert (PI) ... View Video
SPECIALTY GUIDELINE MANAGEMENT - Caremark
FDA-Approved Indication: Gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals ... Return Doc
DOSAGE AND ADMINISTRATION -------------------
2. DOSAGE AND ADMINISTRATION 2.1. Multiple Sclerosis (MS) Only prescribers registered in the MS TOUCH® Prescribing Program may prescribe TYSABRI for multiple sclerosis [see Warnings and Precautions (5.2)].The recommended dose of ... Retrieve Here
HIGHLIGHTS OF PRESCRIBING INFORMATION Observe Patients During ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI. ... Document Viewer
NovoLog - Food And Drug Administration
NovoLog is available in the following package sizes: each presentation contains 100 units of insulin aspart per mL (U-100). 10 mL vials 3 mL PenFill cartridges for the 3 mL PenFill cartridge delivery device (with or without the addition of a NovoPen ® ... Read Here
No comments:
Post a Comment